Indications for IVIG in rheumatic diseases.

Area of Science:

• Rheumatology
• Immunology
• Pharmacology

Background:

• Intravenous immunoglobulin (IVIG) use for immune-driven diseases is expanding.
• Concerns about transmissible agents and rising demand have caused global IVIG shortages.
• Existing guidelines for IVIG use, like the 2011 England and Wales guideline, are being updated.

Purpose of the Study:

• To review current applications of IVIG in rheumatic diseases.
• To provide guidance for rheumatologists on appropriate IVIG use.
• To address the evidence gaps and benefits of IVIG in specific rheumatic conditions.

Main Methods:

• Literature review of IVIG efficacy in rheumatic diseases.
• Analysis of existing national guidelines for IVIG administration.
• Synthesis of evidence for IVIG in various immune-mediated conditions.

Main Results:

• Evidence for IVIG benefit is variable across rheumatic diseases.
• IVIG shows promise in immune thrombocytopenia (ITP), Guillain-Barré syndrome, and chronic inflammatory demyelinating polyneuropathy.
• Positive outcomes reported for systemic lupus erythematosus (SLE), idiopathic inflammatory myopathies, and ANCA-associated vasculitides.

Conclusions:

• IVIG is a valuable therapeutic option for select rheumatic and immune-driven conditions.
• Further research is needed to clarify IVIG's role and optimize its use in rheumatology.
• This review serves as a practical resource for clinicians managing patients with rheumatic diseases requiring IVIG therapy.